Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/15/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
NCT06713616
Recruiting
The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Mood Institute, Milford, Connecticut
Conditions: Depression
Register for Updates
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
NCT05473910
Recruiting
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Yale, New Haven, Connecticut
Conditions: AML, Myelodysplastic Syndromes, ALL, Adult
Register for Updates
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
NCT02530073
Recruiting
The rationale for fetal therapy in severe congenital diaphragmatic hernia (CDH) is to restore adequate lung growth for neonatal survival.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Congenital Diaphragmatic Hernias
Register for Updates
Feasibility Study on PoRi Device
NCT06842901
Recruiting
This study is a feasibility study of a new device that moves the hand of patients with spasticity to reduce hand muscle tone. The device's ability to improve spasticity before and after a 20-minute session with the device at Yale New Haven Hospital's outpatient clinic of Physical Medicine \& Rehabilitation, or the Inpatient Rehabilitation Unit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: , Yale New Haven Hospital's Physical Medicine & Rehabilitation (PM&R) outpatient clinic, New Haven, Connecticut
Conditions: Hand Spasticity
Register for Updates
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
NCT04210492
Recruiting
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut
Conditions: Non-small Cell Lung Cancer
Register for Updates
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Register for Updates
Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study
NCT05279092
Recruiting
The objective of this phase 2 study is to investigate the efficacy of Dexamethasone sodium phosphate (DEX) plus Methylprednisolone acetate (MPA) in combination with plain bupivacaine (B) compared with Liposomal Bupivacaine (LB) in combination with plain bupivacaine on post-surgical pain control among patients undergoing unilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Yale New Haven Hospital Saint Raphael Campus, New Haven, Connecticut
Conditions: Total Knee Replacement, Knee Arthroplasty
Register for Updates
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
NCT05547048
Recruiting
The purpose of this 2-site (CT, AL) study is to test innovative interventions to reduce stigma and improve the pre-exposure prophylaxis (PrEP) and opioid use disorder (OUD) care continua in women involved in the criminal justice system (WICJ). This study evaluates a newly validated PrEP decision aid and eHealth for integrated PrEP and MOUD compared to a decision aid-only for WICJ with OUD.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Yale University, New Haven, Connecticut
Conditions: HIV, Opioid Use Disorder, eHealth
Register for Updates
Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2
NCT05736549
Recruiting
The objective of this study is to investigate the efficacy of Dexamethasone sodium phosphate plus Methylprednisolone acetate in combination with plain bupivacaine ((B-DEX-MPA) compared with Liposomal Bupivacaine in combination with plain bupivacaine (B-LB) on post-surgical pain control among patients undergoing bilateral total knee arthroplasty (TKA) to asses if perineural B-DEX-MPA will result in superior analgesia efficacy as compared to B-LB. This study will also assess if perineural B-DEX-M... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Yale New Haven Hospital Saint Raphael Campus, New Haven, Connecticut
Conditions: Total Knee Replacement, Knee Arthroplasty
Register for Updates
Comparing Mirror Therapy Rehabilitation Device to Conventional Mirror Therapy
NCT06842888
Recruiting
This is a randomized controlled trial which will compare conventional mirror therapy with mirror therapy using the Miraπ device which physically moves a patient's affected limb. This study will use two parallel groups: (1) receiving conventional mirror therapy as a part of the standard of care as conducted by the participant's clinical care team and (2) receiving mirror therapy with the Miraπ device as conducted by study personnel with the oversight of the participant's clinical care team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Rehabilitation and Wellness Center at the Milford Campus of Bridgeport Hospital, Milford, Connecticut
Conditions: Stroke, Pain, Impaired Motor Function
Register for Updates
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut
Conditions: Solid Tumors
Register for Updates